United Therapeutics Stock Performance
| UTHR Stock | USD 235.31 3.53 1.52% |
United Therapeutics has a performance score of 6 on a scale of 0 to 100. The entity has a beta of 0.15, which indicates not very significant fluctuations relative to the market. As returns on the market increase, United Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding United Therapeutics is expected to be smaller as well. United Therapeutics right now has a risk of 1.55%. Please validate United Therapeutics maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if United Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in United Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak technical indicators, United Therapeutics may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
Actual Historical Performance (%)
One Day Return (1.40) | Five Day Return (2.61) | Year To Date Return 1.95 | Ten Year Return 140.94 | All Time Return 3.7 K |
Last Split Factor 2:1 | Last Split Date 2009-09-23 |
1 | United Therapeutics Co. Shares Sold by Teza Capital Management LLC | 03/06/2024 |
2 | Disposition of 5955 shares by Martine Rothblatt of United Therapeutics at 237.6187 subject to Rule 16b-3 | 03/14/2024 |
3 | Disposition of 15000 shares by Martine Rothblatt of United Therapeutics at 129.49 subject to Rule 16b-3 | 03/19/2024 |
4 | Disposition of 1492 shares by Martine Rothblatt of United Therapeutics at 241.053 subject to Rule 16b-3 | 03/25/2024 |
5 | Are You a Momentum Investor This 1 Stock Could Be the Perfect Pick | 03/28/2024 |
6 | Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA inhalation powder | 04/01/2024 |
7 | Disposition of 1477 shares by Martine Rothblatt of United Therapeutics at 230.5177 subject to Rule 16b-3 | 04/02/2024 |
8 | Disposition of 3057 shares by Martine Rothblatt of United Therapeutics at 231.692 subject to Rule 16b-3 | 04/03/2024 |
9 | United Therapeutics EVP sells over 1.3m in company stock | 04/04/2024 |
10 | We Ran A Stock Scan For Earnings Growth And United Therapeutics Passed With Ease | 04/05/2024 |
11 | Disposition of 113 shares by Martine Rothblatt of United Therapeutics at 239.63 subject to Rule 16b-3 | 04/08/2024 |
12 | United Therapeutics chairperson CEO sells 4.73m in stock | 04/09/2024 |
13 | United Therapeutics CEO Martine Rothblatt sells over 6.8 million in company stock | 04/11/2024 |
14 | Disposition of 271 shares by Martine Rothblatt of United Therapeutics at 238.8881 subject to Rule 16b-3 | 04/12/2024 |
15 | United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference | 04/16/2024 |
| Begin Period Cash Flow | 961.2 M |
United |
United Therapeutics Relative Risk vs. Return Landscape
If you would invest 21,911 in United Therapeutics on January 18, 2024 and sell it today you would earn a total of 1,620 from holding United Therapeutics or generate 7.39% return on investment over 90 days. United Therapeutics is currently generating 0.1251% in daily expected returns and assumes 1.5466% risk (volatility on return distribution) over the 90 days horizon. In different words, 13% of stocks are less volatile than United, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
United Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for United Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as United Therapeutics, and traders can use it to determine the average amount a United Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0809
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | UTHR | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.55 actual daily | 13 87% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average United Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of United Therapeutics by adding it to a well-diversified portfolio.
United Therapeutics Fundamentals Growth
United Stock prices reflect investors' perceptions of the future prospects and financial health of United Therapeutics, and United Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on United Stock performance.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.42 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 8.8 B | ||||
| Shares Outstanding | 47.06 M | ||||
| Price To Earning | 23.49 X | ||||
| Price To Book | 1.83 X | ||||
| Price To Sales | 4.70 X | ||||
| Revenue | 2.33 B | ||||
| Gross Profit | 1.78 B | ||||
| EBITDA | 1.39 B | ||||
| Net Income | 984.8 M | ||||
| Cash And Equivalents | 2.26 B | ||||
| Cash Per Share | 49.55 X | ||||
| Total Debt | 700 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 8.10 X | ||||
| Book Value Per Share | 127.23 X | ||||
| Cash Flow From Operations | 978 M | ||||
| Earnings Per Share | 19.82 X | ||||
| Market Capitalization | 11.06 B | ||||
| Total Asset | 7.17 B | ||||
| Retained Earnings | 6.03 B | ||||
| Working Capital | 2.75 B | ||||
| Current Asset | 1.28 B | ||||
| Current Liabilities | 440.82 M | ||||
About United Therapeutics Performance
To evaluate United Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when United Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare United Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand United Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents United's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 158.47 | 150.55 | |
| Return On Tangible Assets | 0.14 | 0.15 | |
| Return On Capital Employed | 0.19 | 0.20 | |
| Return On Assets | 0.14 | 0.14 | |
| Return On Equity | 0.16 | 0.17 |
Things to note about United Therapeutics performance evaluation
Checking the ongoing alerts about United Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for United Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| United Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 97.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from businesswire.com: United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference |
- Analyzing United Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether United Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining United Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating United Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of United Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of United Therapeutics' stock. These opinions can provide insight into United Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.626 | Earnings Share 19.82 | Revenue Per Share 49.733 | Quarterly Revenue Growth 0.251 | Return On Assets 0.1122 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.